Loading company…
Mirugen develops cell reprogramming therapies for retinal diseases.
Mirugen uses sequencing, bioinformatics, and screening to identify factors that may convert one cell type into another. Its research targets Muller Glial cells to regenerate photoreceptors for conditions including Retinitis Pigmentosa. Founded in 2022 and based in Melbourne, Australia, it raised AUD 4.5 million in seed funding in August 2025.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in